Global Pull Incentives for Better Antibacterials: The UK Leads the Way.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Antibiotics re-booted-time to kick back against drug resistance.npj antimicrobials and resistance · 2025
   Review
2. Pricing, Procurement and Reimbursement Policies for Incentivizing Market Entry of Novel Antibiotics and Diagnostics: Learnings from 10 Countries Globally.Applied health economics and health policy · 2024
   Review
3. Pandemic preparedness-political perspectives.Sustainable microbiology · 2024
   Review
4. Small-Molecule Antibiotic Drug Development: Need and Challenges.ACS infectious diseases · 2023
   Review
5. The effect of antibiotic usage on resistance in humans and food-producing animals: a longitudinal, One Health analysis using European data.Frontiers in public health · 2023
   Article

Corrections and comments

• Comment on
  Can the UK 'Netflix' Payment Model Boost the Antibacterial Pipeline?2023

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as